EP 224: Genomic newborn screening in Australia with Zornitza Stark of the University of Melbourne

EP 224: Genomic newborn screening in Australia with Zornitza Stark of the University of Melbourne

by Sano Genetics

Life & Natural Systems Medicine & Health MBNPublic health and preventive medicineMBNCMedical screening
🎙 Sano Genetics 👥 942 📅 January 29, 2026 ⏱ 49 min 👁 64 📄 expert opinion 🧭 2026-08-16
Available in: English (current) Français

Keywords

newborn screeningwhole genome sequencinggenomic medicinecascade testinghealth policy

Summary

In this episode of The Genetics Podcast, host Patrick Short interviews Professor Zornitza Stark, a clinical geneticist and co-leader of the BabyScreen+ study in Australia. The discussion centers on the feasibility and implications of genomic newborn screening (gNBS). Stark describes the BabyScreen+ study, which sequenced the genomes of 1,000 newborns using existing dried blood spots, screening for over 600 early-onset treatable conditions. They found 16 screen-positive cases, including a severe immunodeficiency that was successfully treated, and many conditions not detected by standard biochemical screening. The conversation covers the challenges of scaling up such programs, including automation, variant interpretation, and the need for health economic evaluations. Stark highlights the variability in gene lists across global studies, with only 80 genes common among four major studies, and the importance of harmonizing criteria. They also discuss the ethical and practical aspects of cascade testing, which identified 20 affected relatives, and the need for robust psychosocial support. The episode explores future directions, including offering additional screening for conditions like familial hypercholesterolemia and neurodevelopmental disorders, and the potential for reusing genomic data over a lifetime. Stark emphasizes the need for large-scale studies and policy alignment to enable equitable implementation.

194 words

Critical Evaluation

Value of the Information & Strength of the Argument

The value of the information is high, as it provides a detailed, expert perspective on a rapidly evolving field. Stark offers concrete data from the BabyScreen+ study, such as the 16 positive results and the cascade testing outcomes, which ground the discussion in real-world evidence. The argumentation is well-structured, addressing feasibility, clinical impact, and broader implications. Stark also acknowledges uncertainties, such as the lack of long-term outcome data and the variability in gene lists across studies, which adds credibility. The discussion is balanced, considering both benefits and risks, and includes insights from other major studies like Guardian and Baby Detect. The reasoning is logical and evidence-based, though it is primarily an opinion piece rather than a systematic review.

127 words

Title / Content Match

The title accurately reflects the content, which focuses on genomic newborn screening in Australia, featuring Zornitza Stark and her work on the BabyScreen+ study.

Quality & Reliability

8/10

The discussion is led by a leading clinical geneticist and researcher directly involved in the BabyScreen+ study, providing credible expert insights. The content is based on a peer-reviewed publication and practical experience, but is primarily an interview and opinion rather than a systematic review or original data presentation.

Chapters

Cited Sources

Concurring Sources

Contribution & Novelties

This episode provides an expert overview of the BabyScreen+ study and its implications for genomic newborn screening. It offers unique insights into the practical challenges of implementing such programs, including automation, gene list selection, and cascade testing. The discussion highlights the need for harmonization across studies and the importance of health economic evaluations. The episode also touches on the potential for reusing genomic data over a lifetime, which is a novel concept.

Pour aller plus loin :

  • Genomic newborn screening: current status and future directions — A comprehensive review of the field.
  • Wilson and Jungner criteria — The classic framework for screening programs, relevant to the discussion on gene list selection.
  • Cascade testing — A key concept in genetic testing, discussed in the episode.

124 words

Radar Profile

The radar chart shows a balanced profile with high scores in information quantity, quality, and reliability, and a slightly lower score in technical level, reflecting the expert but accessible nature of the discussion. This indicates a highly informative and credible episode, suitable for a broad audience interested in genomics and public health.

Reliability 8/10